We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Continue to Hold EW Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
Edwards Lifesciences sees growth in Surgical Structural Heart, led by RESILIA tissue adoption.
EW's TAVR and TMTT segments posted strong Q3 gains supported by new approvals and global rollouts.
Macro pressures, higher COGS and ongoing litigation continue to challenge Edwards' profitability.
Edwards Lifesciences Corporation (EW - Free Report) is well-poised to grow in the coming quarters owing to its Surgical Structural Heart, which pioneered the RESILIA tissue. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform is positioned for continued global leadership and strong, sustainable growth. Further, the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business has seen consistent growth over the past few quarters, with Edwards efficiently scaling its fast-growing businesses. Meanwhile, macroeconomic impacts and litigation expenses may hurt its operations.
In the past year, this Zacks Rank #3 (Hold) stock has rallied 13.4% against the 2.1% fall of the industry. The S&P 500 composite has risen 15.2% in the same time frame.
The renowned global medical device company has a market capitalization of $48.33 billion. Edward Lifesciences’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.89%.
Let’s delve deeper.
Upsides for EW Stock
Surgical Structural Heart, a Promising Business: The business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. In the third quarter of 2025, the segment grew 5.3% from the prior-year level, driven by strong global adoption of Edwards’ premium resilient technologies, including INSPIRIS, MITRIS and KONECT. The company continues to see positive procedure growth globally for the many patients treated surgically, including those undergoing complex procedures.
Additionally, management highlighted strong surgical valve performance in the recent PARTNER III seven-year data. Meanwhile, in the past few quarters, the company made progress in advancing important innovations worldwide, including the CE Mark approval for KONECT in Europe and the launch of MITRIS in China.
Image Source: Zacks Investment Research
TAVR Holds Potential: The TAVR business closed the third quarter of 2025 with 10.6% year-over-year growth. Edwards' strong competitive position and pricing remained stable globally. In the United States, the clinical conversations around the EARLY TAVR trial data are leading to a renewed focus on streamlining the management of patients with severe aortic stenosis (AS), enabling closer follow-up and more timely treatment of patients with aortic stenosis. In Europe, the broad-based adoption of the SAPIEN platform and the exit of a competitor resulted in a rebalancing of market share and a modest contribution to Edwards’ sales.
In May, the company received FDA approval for its SAPIEN 3 platform for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Following the CE Mark for the Alterra system for congenital heart patients, Edwards is rolling out this therapy in Europe, and initial feedback from clinicians has been positive.
TMTT Portfolio Looks Robust: Edwards is on track for strong, sustainable growth through its advancement in the long-term TMTT strategy, driven by a growing portfolio of innovative therapies. In the third quarter, the segment witnessed a 53% increase in sales compared to the prior year, driven by the strong performance of both PASCAL and EVOQUE systems globally. The adoption of differentiated PASCAL technology is expanding in both new and existing sites worldwide.
Meanwhile, Edwards is making strides with the EVOQUE commercial rollout, successfully activating new sites in both the United States and Europe (other than initial trial centers). In April, Edwards’ SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic mitral regurgitation who are unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy.
Downsides for EW Stock
Macro Concerns Put Pressure on the Bottom Line: Edwards’ extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The industrywide increase in inflationary pressure, supply constraints stemming from geopolitical complications and regulatory changes are weighing heavily on the company’s operating results. The business is also currently experiencing staffing shortages within the hospital systems. This is also putting significant pressure on the margins of Edwards. In the third quarter of 2025, these issues resulted in a 31.3% increase in COGS.
Litigation Charges May Slow Down Growth: In recent years, Edwards has been involved in substantial litigation regarding patent and other intellectual property rights with its competitors. Regardless of the outcome, these matters and regulatory actions, recalls or other actions can materially impact its business, reputation, and ability to attract and retain customers.
EW Stock Estimate Trend
The Zacks Consensus Estimate for Edwards Lifesciences’ 2025 earnings per share (EPS) has increased 1 cent to $2.59 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $6.03 billion. This suggests a 1% rise from the year-ago reported number.
BrightSpring Health Serviceshas an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 45.1%. BTSG shares have surged 91.5% compared with the 1.2% rise in the past year.
Illumina, sporting a Zacks Rank #1, has an earnings yield of 3.7% compared to the industry’s -17.9% yield. Shares of the company have dropped 8.6% in the past year against the industry’s 8.6% growth. ILMN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.7%.
Insulet, carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 29% compared to the industry’s 13.2% growth. Shares of the company have risen 8% against the industry’s 3.7% fall. PODD’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.8%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Should You Continue to Hold EW Stock in Your Portfolio?
Key Takeaways
Edwards Lifesciences Corporation (EW - Free Report) is well-poised to grow in the coming quarters owing to its Surgical Structural Heart, which pioneered the RESILIA tissue. The company’s Transcatheter Aortic Valve Replacement (“TAVR”) platform is positioned for continued global leadership and strong, sustainable growth. Further, the Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business has seen consistent growth over the past few quarters, with Edwards efficiently scaling its fast-growing businesses. Meanwhile, macroeconomic impacts and litigation expenses may hurt its operations.
In the past year, this Zacks Rank #3 (Hold) stock has rallied 13.4% against the 2.1% fall of the industry. The S&P 500 composite has risen 15.2% in the same time frame.
The renowned global medical device company has a market capitalization of $48.33 billion. Edward Lifesciences’ earnings surpassed estimates in each of the trailing four quarters, delivering an average surprise of 8.89%.
Let’s delve deeper.
Upsides for EW Stock
Surgical Structural Heart, a Promising Business: The business pioneered the innovative RESILIA tissue, which is backed by more than 40 years of the company’s tissue technology leadership. In the third quarter of 2025, the segment grew 5.3% from the prior-year level, driven by strong global adoption of Edwards’ premium resilient technologies, including INSPIRIS, MITRIS and KONECT. The company continues to see positive procedure growth globally for the many patients treated surgically, including those undergoing complex procedures.
Additionally, management highlighted strong surgical valve performance in the recent PARTNER III seven-year data. Meanwhile, in the past few quarters, the company made progress in advancing important innovations worldwide, including the CE Mark approval for KONECT in Europe and the launch of MITRIS in China.
Image Source: Zacks Investment Research
TAVR Holds Potential: The TAVR business closed the third quarter of 2025 with 10.6% year-over-year growth. Edwards' strong competitive position and pricing remained stable globally. In the United States, the clinical conversations around the EARLY TAVR trial data are leading to a renewed focus on streamlining the management of patients with severe aortic stenosis (AS), enabling closer follow-up and more timely treatment of patients with aortic stenosis. In Europe, the broad-based adoption of the SAPIEN platform and the exit of a competitor resulted in a rebalancing of market share and a modest contribution to Edwards’ sales.
In May, the company received FDA approval for its SAPIEN 3 platform for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients. Following the CE Mark for the Alterra system for congenital heart patients, Edwards is rolling out this therapy in Europe, and initial feedback from clinicians has been positive.
TMTT Portfolio Looks Robust: Edwards is on track for strong, sustainable growth through its advancement in the long-term TMTT strategy, driven by a growing portfolio of innovative therapies. In the third quarter, the segment witnessed a 53% increase in sales compared to the prior year, driven by the strong performance of both PASCAL and EVOQUE systems globally. The adoption of differentiated PASCAL technology is expanding in both new and existing sites worldwide.
Meanwhile, Edwards is making strides with the EVOQUE commercial rollout, successfully activating new sites in both the United States and Europe (other than initial trial centers). In April, Edwards’ SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic mitral regurgitation who are unsuitable for surgery or transcatheter edge-to-edge (TEER) therapy.
Downsides for EW Stock
Macro Concerns Put Pressure on the Bottom Line: Edwards’ extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The industrywide increase in inflationary pressure, supply constraints stemming from geopolitical complications and regulatory changes are weighing heavily on the company’s operating results. The business is also currently experiencing staffing shortages within the hospital systems. This is also putting significant pressure on the margins of Edwards. In the third quarter of 2025, these issues resulted in a 31.3% increase in COGS.
Litigation Charges May Slow Down Growth: In recent years, Edwards has been involved in substantial litigation regarding patent and other intellectual property rights with its competitors. Regardless of the outcome, these matters and regulatory actions, recalls or other actions can materially impact its business, reputation, and ability to attract and retain customers.
EW Stock Estimate Trend
The Zacks Consensus Estimate for Edwards Lifesciences’ 2025 earnings per share (EPS) has increased 1 cent to $2.59 in the past 30 days.
The Zacks Consensus Estimate for the company’s 2025 revenues is pegged at $6.03 billion. This suggests a 1% rise from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are BrightSpring Health Services (BTSG - Free Report) , lllumina (ILMN - Free Report) and Insulet (PODD - Free Report) .
BrightSpring Health Serviceshas an estimated long-term earnings growth rate of 53.3% compared with the industry’s 15.5% growth. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 45.1%. BTSG shares have surged 91.5% compared with the 1.2% rise in the past year.
BTSG sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Illumina, sporting a Zacks Rank #1, has an earnings yield of 3.7% compared to the industry’s -17.9% yield. Shares of the company have dropped 8.6% in the past year against the industry’s 8.6% growth. ILMN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 6.7%.
Insulet, carrying a Zacks Rank #2 (Buy), has a long-term earnings growth rate of 29% compared to the industry’s 13.2% growth. Shares of the company have risen 8% against the industry’s 3.7% fall. PODD’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 17.8%.